quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:14:51·14d
SECFiling
Verastem Inc. logo

SEC Form DEF 14A filed by Verastem Inc.

VSTM· Verastem Inc.
Health Care
Original source

Companies

  • VSTM
    Verastem Inc.
    Health Care

Recent analyst ratings

  • Mar 12UpdateBTIG Research$19.00
  • Feb 4UpdateH.C. Wainwright$18.00
  • Oct 16UpdateCantor Fitzgerald-
  • Apr 10UpdateJefferies$15.00
  • Mar 24UpdateH.C. Wainwright$10.00
  • Dec 31UpdateBTIG Research$20.00

Related

  • PR23h
    Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
  • PR14d
    Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers
  • PR21d
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.
  • INSIDER31d
    SEC Form 4 filed by Calkins Daniel
  • PR37d
    Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
  • PR37d
    Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers
  • ANALYST42d
    BTIG Research resumed coverage on Verastem with a new price target
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022